A phase II study of TR105 in patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib.

被引：0
|
作者：
Duffy, Austin G. [1 ]
Rahma, Osama E. [1 ]
Ulahannan, Susanna Varkey [1 ]
Fioravanti, Suzanne [1 ]
Venkatesan, Aradhana [1 ]
Turkbey, Ismail B. [1 ]
Choyke, Peter L. [1 ]
Trepel, Jane B. [1 ]
Figg, William Douglas [1 ]
Greten, Tim F. [1 ]
机构：
[1] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15177
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
    Lee, Dae-Won
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Yu, Su Jong
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Kim, Tae-Yong
    Han, Sae-Won
    Oh, Youn
    Im, Seock-Ah
    Kim, Tae-You
    Lee, Youngeun
    Kim, Haeryoung
    Lee, Kyung-Hun
    CLINICAL CANCER RESEARCH, 2021, 27 (03) : 713 - 718
  • [32] Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomised Phase II trial
    Yen, C.
    Kim, T. Y.
    Feng, Y. H.
    Chao, Y.
    Lin, D. Y.
    Studeny, M.
    Hocke, J.
    Huang, D. C. L.
    Ryoo, B. Y.
    Cheng, A. L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S612 - S612
  • [33] A phase II study of arsenic trioxide (ATO) in patients with advanced hepatocellular carcinoma (HCC)
    Rodgers, H. A.
    Katta, S. F.
    Malani, A. K.
    Willis, M.
    Markowitz, A. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results
    O'Neil, Bert H.
    Bendell, Johanna C.
    Modiano, Manuel R.
    Machiels, Jean-Pascal H.
    Versola, Melissa Jo
    Hodge, Jeff Paul
    Sawarna, Karen
    Tse, Nielson
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [35] Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Palmer, Daniel H.
    Ma, Yuk Ting
    Peck-Radosavljevic, Markus
    Ross, Paul J.
    Graham, Janet Shirley
    Fartoux, Laetitia
    Deptala, Andrzej
    Wenz, Arne
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Meyer, Tim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [36] Phase II trial of tepotinib vs sorafenib for treatment-naive advanced hepatocellular carcinoma (HCC) in Asian patients
    Ryoo, B-Y.
    Ren, Z.
    Kim, T-Y.
    Pan, H.
    Rau, K-M.
    Choi, H. J.
    Park, J-W.
    Kim, J. H.
    Yen, C-J.
    Kim, B-H.
    Zhou, D.
    Straub, J.
    Zhao, C.
    Qin, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [37] Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
    Ghassan K. Abou-Alfa
    Chia-Jui Yen
    Chih-Hung Hsu
    Joseph O’Donoghue
    Volkan Beylergil
    Shutian Ruan
    Neeta Pandit-Taskar
    Bolorsukh Gansukh
    Serge K. Lyashchenko
    Jennifer Ma
    Peter Wan
    Yu-Yun Shao
    Zhong-Zhe Lin
    Catherine Frenette
    Bert O’Neil
    Lawrence Schwartz
    Peter M. Smith-Jones
    Toshihiko Ohtomo
    Takayoshi Tanaka
    Hideo Morikawa
    Yuko Maki
    Norihisa Ohishi
    Ya-Chi Chen
    Tamara Agajanov
    Frederic Boisserie
    Laura Di Laurenzio
    Ray Lee
    Steven M. Larson
    Ann-Lii Cheng
    Jorge A. Carrasquilo
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 421 - 429
  • [38] Perspective Phase II Study of Combination Sorafenib Plus Mitomycin-C in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
    Dima, G.
    Lucia, M.
    La Gattuta, G.
    Toscano, R.
    Olivito, V.
    Talarico, R.
    Cervo, G. L.
    Filippelli, G.
    ONCOLOGY, 2009, 77 : 142 - 143
  • [39] PERSPECTIVE PHASE II STUDY OF COMBINATION SORAFENIB PLUS MITOMYCIN-C IN THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
    Gianluca, Dima
    Maria, Lucia
    Gaetana, La Gattuta
    Rosa, Toscano
    Virginia, Olivito
    Rosa, Talarico
    Luca, Cervo Gian
    Gianfranco, Filippelli
    ANNALS OF ONCOLOGY, 2009, 20
  • [40] Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
    Abou-Alfa, Ghassan K.
    Niedzwieski, Donna
    Knox, Jennifer J.
    Kaubisch, Andreas
    Posey, James
    Tan, Benjamin R.
    Kavan, Petr
    Goel, Rakesh
    Murray, John J.
    Bekaii-Saab, Tanios S.
    Tam, Vincent Channing
    Rajdev, Lakshmi
    Kelley, Robin Kate
    Siegel, Abby
    Balletti, Jennifer
    Harding, James J.
    Schwartz, Lawrence Howard
    Goldberg, Richard M.
    Bertagnolli, Monica M.
    Venook, Alan P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345